Stocks and InvestingStocks and Investing
Mon, April 12, 2021
Fri, April 9, 2021
Thu, April 8, 2021
Wed, April 7, 2021
Tue, April 6, 2021

Salveen Richter Downgraded (ACAD) to Hold and Decreased Target to $25 on, Apr 6th, 2021


Published on 2024-10-27 16:07:51 - WOPRAI, Salveen Richter
  Print publication without navigation


Salveen Richter of Goldman Sachs, Downgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Hold and Decreased Target from $73 to $25 on, Apr 6th, 2021.

Salveen has made no other calls on ACAD in the last 4 months.



There are 7 other peers that have a rating on ACAD. Out of the 7 peers that are also analyzing ACAD, 4 agree with Salveen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold on, Wednesday, March 10th, 2021
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Tuesday, March 9th, 2021
  • Neena Bitritto-Garg of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $35 on, Tuesday, March 9th, 2021
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $27 on, Tuesday, March 9th, 2021


These are the ratings of the 3 analyists that currently disagree with Salveen


  • Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $30 on, Monday, April 5th, 2021
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $43 on, Tuesday, March 9th, 2021
  • Danielle Brill of "Raymond James" Downgraded from Strong Buy to Buy and Decreased Target to $35 on, Tuesday, March 9th, 2021